The Challenging Solid Tumor Microenvironment The challenging tumor microenvironment is another obstacle with CAR T-cell therapy of solid tumors. As reported by Newick and colleagues, significant hurdles include: Trafficking: CAR …
CAR T-Cell Therapy HCP Guide – Challenges: Car-T and Solid Tumors Read More
October 19, 2017 (Medical News Today) Immunotherapy, which activates a patient’s own immune system to attack cancer, is still a new approach to treating cancer. Researchers from the Massachusetts Institute …
‘Synthetic gene circuit’ may improve effectiveness of cancer immunotherapy Read More
Solid Tumor Research: Ongoing CAR T-cell therapy has shown great success in hematologic malignancies, such as non-Hodgkin’s lymphoma (diffuse large B-cell lymphoma (DLBCL), follicular lymphoma), acute lymphoblastic leukemia (ALL), chronic …
CAR T-Cell Therapy HCP Guide – Solid Tumors Read More
ZUMA-3 and ZUMA-4 Trials In addition to the October 2017 approval for Non-Hodgkin lymphoma, Yescarta (axicabtagene ciloleucel) has shown impressive early results in difficult-to-treat patients with ALL. As reported in …
CAR T-Cell Therapy HCP Guide – Efficacy and Safety of Zuma Trials Read More